Skip to search formSkip to main contentSkip to account menu

ADR-529

Known as: ADR 529, ADR529 
National Institutes of Health

Related topics

Related topics

2 relations

Broader (2)

DexrazoxaneDexrazoxane hydrochloride

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2004
2004
Reducing doxorubicin cardiotoxicity in the rat using deferred treatment with ADR-529
SummaryThe purpose of this study was to evaluate the optimal timing of ADR-529 administration to protect rats treated with… 
2004
2004
A Sensitive and Specific Procedure for Quantitation of ADR-529 in Biological Fluids by High-Performance Liquid Chromatography (HPLC) with Column Switching and Amperometric Detection
An HPLC method using electrochemical detection (ED) has been validated for the determination of ADR-529 in plasma and urine using… 
2004
2004
The cardioprotector ADR-529 and high-dose epirubicin given in combination with cyclophosphamide, 5-fluorouracil, and tamoxifen: a phase I study in metastatic breast cancer
The purpose of this study was to determine the maximal tolerble dose (MTD) of epirubicin and ADR-529 given in combination with… 
1999
1999
Effects of wild-type p53 expression on the quantity and activity of topoisomerase IIalpha and beta in various human cancer cell lines.
The p53 null HL-60 cell line was transfected with plasmids coding for either the wild-type p53 or mutant p53 gene. The stable… 
Review
1996
Review
1996
A Review of the Modulation of Cisplatin Toxicities by Chemoprotectants
In 1988, Dr. Brian Leyland-Jones questioned “Whither the Modulation of Platinum” in an editorial in the Journal of the National… 
1992
1992
In vitro effects of three iron chelators on mitogen-activated lymphocytes: identification of differences in their mechanisms of action.
1992
1992
Mechanisms of anthracycline - induced cardiac toxicity: The role of iron binding
Review
1991
Review
1991
ICRF-187 (ADR-529) cardioprotection against anthracycline-induced cardiotoxicity: clinical and preclinical studies.
Anthracyclines are anticancer agents that are effective in a wide range of tumors. Unfortunately, their activity is limited by… 
Review
1991
Review
1991
Toxicity profile of dexrazoxane (Zinecard, ICRF-187, ADR-529, NSC-169780), a modulator of doxorubicin cardiotoxicity.
1990
1990
Effects of (+)-1,2-bis(3,5-dioxopiperazin-1-yl)propane (ADR-529) on iron-catalyzed lipid peroxidation.
ADR-529 [(+)-1,2-bis(3,5-dioxopiperazin-1-yl)propane], a nonpolar, cyclic analogue of EDTA, protects against anthracycline… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)